

Susceptibility Profile of Methicillin-Resistant *Staphylococcus aureus* (MRSA) Isolates to Antibiotics and Methanolic Extracts of *Parkia biglobosa* (Jacq) Benth

A. F. Obajuluwa^{1*}, J. A. Onaolapo¹, A. R. Oyi¹ and B. O. Olayinka¹

¹Department of Pharmaceutics and Pharmaceutical Microbiology, Ahmadu Bello University, Zaria, Nigeria.

Authors' contributions

This work was carried out in collaboration between all authors. Author AFO designed the study, performed the statistical analysis, wrote the protocol, and wrote the first draft of the manuscript. Authors JAO and BOO managed the analyses of the study. Author ARO managed the literature searches. All authors read and approved the final manuscript.

Research Article

Received 18th August 2012
Accepted 12th November 2012
Published 24th May 2013

ABSTRACT

Aims: To study the susceptibility profile of methicillin-resistant *Staphylococcus aureus* (MRSA) isolates from orthopaedic patients to antibiotics and methanolic extracts of *Parkia biglobosa*.

Background: Antimicrobial resistance in *Staphylococcus aureus* has attained alarming proportions worldwide; with methicillin resistant *Staphylococcus aureus* (MRSA) becoming a major pathogen of public health importance associated with community and hospital acquired infections. Wound infections in orthopaedic patients with multidrug resistant pathogens significantly delay or prevent the union of fractured bones. The increasing prevalence of multidrug resistance in *Staphylococcus aureus* isolates calls for the search for alternative anti-staphylococcal agents.

Methodology: Suspected staphylococcal isolates from wound, skin and bed swab samples from orthopaedic patients in a tertiary hospital in Zaria, Nigeria were characterized by established microbiological procedures and their antibiotic susceptibility pattern determined by the Kirby-Bauer-CLSI modified disc agar diffusion (DAD) technique. The activity of crude methanolic extract of the root, stem bark and leaf of *Parkia biglobosa*

*Corresponding author: Email: funkeyomi6874@gmail.com;

on the isolates determined.

Results: A total of 179 isolates were confirmed *S. aureus*: wounds (24.6%), skin (39.1%) and bed (36.3%). The isolation rates for MRSA from the various sites were: wound (75%), skin (51.4%) and bed (73.8%). Antibiotic susceptibility testing revealed that the isolates were generally resistant to ampicillin (100% for all sites); ceftriazone (wound 69.7%, skin 72.2%, bed 70.8%); gentamicin (wound 54.5%, skin 52.8%, bed 37.5%) and ciprofloxacin (wound 51.5%, skin 47.2%, bed 35.4%). The phytochemical screening of the methanolic extract of the leaf, root and stem bark of *Parkia biglobosa* showed the presence of saponin, tannin, flavonoids and cardiac glycosides. The stem bark of *Parkia biglobosa* showed the greatest activity against all the multidrug resistant MRSA isolates at the 10mg/ml-25mg/ml concentration range used. In the search for alternative antistaphylococcal agents from natural sources, *Parkia biglobosa* will be a possible candidate for further investigation.

Conclusion: There was high prevalence of multidrug resistant *Staphylococcus aureus* isolates from the clinical and surveillance samples from the orthopaedic patients.

Keywords: Methicillin-resistant *Staphylococcus aureus* (MRSA); orthopaedic.

1. INTRODUCTION

The emergence of multi-drug resistant (MDR) strains of *Staphylococcus aureus*, especially the methicillin-resistant *Staphylococcus aureus* (MRSA), has made the chemotherapy of staphylococcal infections in community and hospital settings increasingly challenging. Increased prevalence of these MDR strains of *S. aureus* in different, special patient groups has resulted in poor prognosis of infections. Methicillin resistant *S. aureus* (MRSA) was first discovered in 1961, they were isolates of *S. aureus* which have acquired genes encoding antibiotic resistance to all penicillins including methicillin and other narrow spectrum β lactamase resistant penicillin antibiotics. Since then hospitals worldwide have reported varying proportion of MRSA among *S. aureus* isolates [1]. Wound infections in orthopaedic patients with such MDR strains significantly delay or prevent the union of fractured bones. Reports of development of resistance to a wide range of anti-staphylococcal drugs like the glycopeptides; vancomycin and teicoplanin, linezolid and strengraminquinupristin/dalfopristin mixture necessitates the search for new anti-staphylococcal agents of plant origin.

Parkia biglobosa is a multipurpose fodder tree that belongs to the family MIMOSACEAE [2]. Popularly called the "African locust bean tree", they are known to occur in a diversity of agroecological zones from tropical rainforest where the rain is high to the arid zone where it is low. The height ranges from 7 - 30 m. It is crown large and spreads wide with low branches, the leaves are alternate, dark green, bipinnate and about 8 – 30 mm x 1.5 – 8 mm in size with about 13 - 60 pairs of leaflets of distinct venation on along rachis. The pods are pink brown to dark brown when matured, they are up to 45 cm long and 2 cm wide. Each pod contains up to 30 seeds embedded in a yellow pericarp.

The seeds are relatively large with an average weight of 0.26 g and have a hard testa. [3]. The bark is used as a mouthwash, vapour inhalant for toothache, or for ear complaints. It is macerated in baths for leprosy and used for bronchitis, pneumonia, skin infectious, sores, ulcers bilharzias, washes for fever, malaria, diarrhea, violent colic and vomiting, sterility venereal diseases, guinea worm, oedema and tickets and as a poison antidote. Leaves are used in lotions for sore eyes, burns, haemorrhoids and toothache. Seed is taken for tension

and pulp for fevers, as a diuretic and as a mild purgative. Roots are used in a lotion for sore eye [4].

This paper reports the susceptibility profile of methicillin-resistant *Staphylococcus aureus* (MRSA) isolates to antibiotics and methanolic extracts of *Parkia biglobosa*.

2. MATERIALS AND METHODS

2.1 Bacteriology

Ethical approval was obtained from the appropriate authority of the hospital, after which suspected staphylococcal isolates from clinical (wound swab) and surveillance (skin, bed) samples from orthopaedic patients in a tertiary referral hospital in Zaria, Nigeria over a three-month period were characterized by established microbiological procedures. Isolates that were Gram-positive cocci, catalase positive and coagulase positive were considered *S. aureus* in this study.

2.2 Detection of Methicillin Resistance

This was carried out according to Clinical Laboratory Standards Institute [5] guidelines using oxacillin in agar screen test whereby all phenotypic MRSA isolates were spot - inoculated onto Mueller-Hinton agar (MHA) supplemented with 6µg/ml oxacillin and 4% sodium chloride, from a 0.5 McFarland standard suspension. The plates were incubated at 35°C for 24 hours and the isolates that had growth (more than one colony) were considered methicillin resistant.

2.3 Antibiotic Sensitivity Tests

Kirby Bauer – NCCLS (now CLSI) modified disc agar diffusion technique was used [6]. Discrete colonies of isolates on nutrient agar plates were emulsified in 3 ml of phosphate buffered solution (PBS) and the turbidity adjusted to 0.5 McFarland standard. Using sterile swab sticks, the surface of MHA in a 90 mm diameter plate was inoculated with the bacterial suspension by streaking the surface of agar in three directions, rotating the plate approximately 60° to ensure even distribution. The inoculated plates were allowed to dry for 10 minutes before the antibiotic discs: Methicillin (5µg), ampicillin (10µg), vancomycin (30µg), oxacillin (1µg), Gentamicin (10µg), Ceftriaxone (30µg), Pefloxacin (5µg) and ciprofloxacin (5µg) were applied aseptically to the surface of the agar. After 30 minutes of applying the discs the plates were inverted, and incubated at 35°C. Similar treatment was extended to standard *S. aureus* ATCC 25923 which was used as control.

2.4 Collection and Authentication of *Parkia biglobosa*

The plant materials namely leave, roots and stem bark were collected from Samaru-Zaria in Kaduna State, Nigeria. They were authenticated in the herbarium section of the Biological Science Department of Ahmadu Bello University, Zaria with the herbarium number 2846.

2.5 Preparation and Extraction of Plant Samples

Each plant sample was air dried for five days and ground into powder in a mortar, prior to extraction with methanol using soxhlet apparatus. The solvent was thereafter removed and the methanolic extract yielded was stored in the desiccator until needed.

2.6 Phytochemical Screening

The methanolic extract was subjected to phytochemical screening to test for the presence of saponins, tannins, flavonoids, carbohydrates, alkaloids and steroids using standard methods [7,8]

2.7 Antibacterial Activity of Crude Methanolic Extract of Leaves, Roots and Stem Bark of *Parkia biglobosa* to MRSA

The isolates that were found to be MRSA were used for this test, disc agar diffusion method was used. An overnight broth culture of each isolate was used to seed sterile molten MHA medium maintained at 45°C. They were allowed to set and wells (6mm in diameter) were made on them using a sterile standard cork borer. Various concentrations of the plant extract (ranging from 10mg/ml to 25mg/ml) were added to each well. The plates were allowed to stand at room temperature for about one hour and thereafter incubated at 37°C for 24hours. The diameter of each zone of inhibition was measured after incubation.

3. RESULTS AND DISCUSSION

Out of the total number of 211 samples collected, 179 confirmed *S. aureus* isolates were recovered from the clinical and surveillance samples and were distributed as wounds (24.6%), skin (39.1%) and bed (36.3%). The isolation rates for MRSA from the various sites was: wound (75%), skin (51.4%) and bed (73.8%) Table 1 shows the distribution of *S. aureus* and MRSA isolates from the various sample sites.

Table 1. Distribution of *S. aureus* and MRSA isolates

Source	No of sample	<i>S.aureus</i> no %	MRSA no %
Wound	51	44(86.3)	33(75.0)
Skin	80	70(87.5)	37(51.4)
Bed	80	65(81.3)	48(73.8)
Total	211	179(84.8)	118(65.9)

Antibiotic susceptibility testing revealed that the MRSA isolates were generally resistant to ampicillin (100% for all sites); ceftriazone (wound 69.7%, skin 72.2%, bed 70.8%); gentamicin (wound 54.5%, skin 52.8%, bed 37.5%) and ciprofloxacin (wound 51.5%, skin 47.2%, bed 35.4%), this is shown in Fig. 1.




Fig. 1. Percentage resistance of MRSA strains from various sites to antibiotics

AMP: Ampicillin 10 μ g

CRO: Ceftriaxone 30 μ g

VA: Vancomycin 5 μ g

CN: Gentamicin 10 μ g

PEF: Pefloxacin 5 μ g

CIP: Ciprofloxacin 5 μ g

There was high prevalence of multidrug resistance (MDR) *S. aureus* from clinical and surveillance samples. *S. aureus* is among the most common cause of surgical site infection (SSI) in orthopaedic patients [9]. Patients infected with (MDR) microorganisms may shed them into the environment, this is an indication that *S. aureus* can cause nosocomial infection. Centre for Disease Control and Prevention [10] reported that *S. aureus* was the most common cause of nosocomial infections reported in National Nosocomial Surveillance System between 1990 – 1996. *S. aureus* is one of the most common cause of nosocomial infections [11,12,13] The majority of nosocomial infection is caused by a patient's own endogenous microbial flora present upon admission to the hospital [14]. The multidrug resistance (MDR) status of the MRSA isolate suggest limited therapeutic options. The MRSA isolates showed resistance to all the antibiotics used including vancomycin. Vancomycin was believed to have retained activity against MRSA but there is recent alarming increasing emergence of vancomycin resistance to *S. aureus* worldwide [15], even though there are other reports that showed 100% vancomycin susceptibility [16,17]. Frequent use of commonly available antibiotics provided sufficient selective pressure to promote colonization and/or infection with vancomycin resistance enterococci [18] and MRSA eventually resulting in the emergence of vancomycin resistant *S. aureus* [19]. Wound infections in orthopaedic patients with such MDR pathogens is believed to significantly delay or prevent union of fractured bone, leading to long hospital stays [20].

Plants have long been used as a source of therapeutic agents. Plants are known to synthesize antibacterial natural product following microbial attack, to protect them from invasive and pathogenic microorganisms in their environment. Now, workers in the field of

plant medicines research, regard higher plants as living chemical factories that provide a vast number of unusual chemical substances that display a variety of biological actions [21]. The result of the phytochemical screening of the crude methanolic extract of leaf, root and stem bark of *Parkia biglobosa* showed the presence of secondary metabolites which include: saponins, carbohydrate, tannins flavonoids and cardiac glycosides, this is presented in Table 2. These results are consistent with those obtained by Ajaiyeoba [22] by studying the phytochemical and antibacterial properties of *Parkia biglobosa* and *Parkia bicolor* leaf extracts, in Nigeria. Also, these results are in agreement with those obtained by Hall *et al.* [23].

Tables 3 -10 showed the results of the antibacterial activity of the crude extracts of the leaf, root and stem bark of *P. biglobosa*, respectively.

Table 2. Results of phytochemical screening

Metabolites	Methanolic extract of leaf	Methanolic extract of root	Methanolic extract of stem bark
Saponin	+	+	+
Carbohydrate	+	+	+
Alkaloid	-	-	-
Tannins	+	+	+
Flavonoids	+	+	+
Anthraquinones	-	-	-
Cardiac glycosides	+	+	+
Resins	-	-	-

+ present
- absent

The crude methanolic extracts of leaf of *Parkia. biglobosa* at the various concentrations used (10mg/ml to 20 mg/ml) showed no activity against the MRSA isolates from wound but little activity at 25mg/ml against MRSA isolates from skin and bed (Tables 3 and 4).

Table 3. Antibacterial activity of crude extract of leaves of *P. biglobosa* against MRSA isolates from skin

Concentration of extract	Diameter zone of inhibition (% of isolates)		
	No. zone (No activity)	8 – 10mm	11 – 14mm
10mg/ml	36 (100)	-	-
15mg/ml	36 (100)	-	-
20mg/ml	36 (100)	-	-
25mg/ml	27 (75.0)	9 (25.0)	-

Table 4. Antibacterial activity of crude extract of leaves of *P. biglobosa* against MRSA isolates from bed

Concentration of extract	Diameter zone of inhibition (% of isolates)		
	No. zone (No activity)	8 – 10mm	11 – 14mm
10mg/ml	48 (100)	-	-
15mg/ml	48 (100)	-	-
20mg/ml	48 (100)	-	-
25mg/ml	31 (64.6)	17 (35.4)	-

The crude methanolic extract of the root showed no activity against MRSA isolates at 10mg/ml and a very low activity at 15mg/ml however, there was an increased activity at 20mg/ml and 25mg/ml (Tables 5-7).

Table 5. Antibacterial activity of crude extract of roots of *P. biglobosa* against MRSA isolates from wound

Concentration of extract	Diameter zone of inhibition (% of isolates)		
	No. zone (No activity)	8 – 10mm	11 – 14mm
10mg/ml	33 (100)	0	-
15mg/ml	29 (87.9)	4 (12.1)	-
20mg/ml	26 (78.8)	6 (18.2)	1 (3.0)
25mg/ml	22 (66.7)	5 (15.2)	6 (18.2)

Table 6. Antibacterial activity of crude extract of roots of *P. biglobosa* against MRSA isolates from skin

Concentration of extract	Diameter zone of inhibition (% of isolates)		
	No. zone (No activity)	8 – 10mm	11 – 14mm
10mg/ml	36 (100)	-	-
15mg/ml	31 (86.1)	3 (8.3)	2 (5.6)
20mg/ml	20 (55.6)	14 (38.9)	2 (5.6)
25mg/ml	14 (38.9)	15 (41.7)	7 (19.4)

Table 7. Antibacterial activity of crude extracts of roots of *P. biglobosa* against MRSA isolates from bed

Concentration of extract	Diameter zone of inhibition (% of isolates)		
	No. zone (No activity)	8 – 10mm	11 – 14mm
10mg/ml	48 (100)	-	-
15mg/ml	36 (75.0)	9 (18.8)	3 (6.3)
20mg/ml	22 (25.8)	21 (43.8)	5 (10.4)
25mg/ml	16 (33.3)	12 (25.0)	20 (41.7)

The crude methanolic extracts of the stem bark was active at the various concentration used (10mg/ml – 25mg/ml) against MRSA isolates from wound, skin and bed. These activities were concentration dependent (Tables 8-10).

Table 8. Antibacterial activity of crude extract of stem bark of *P. biglobosa* against MRSA isolates from wound

Concentration of extract	Diameter zone of inhibition (% of isolates)		
	No. zone (No activity)	8 – 10mm	11 – 14mm
10mg/ml	30 (90.9)	3 (9.1)	-
15mg/ml	26 (78.8)	7 (21.2)	-
20mg/ml	22 (66.7)	5 (15.2)	6 (18.2)
25mg/ml	21 (63.6)	5 (15.2)	7 (21.2)

Table 9. Antibacterial activity of crude extract of stem bark of *P. biglobosa* against MRSA isolates from skin

Concentration of extract	Diameter zone of inhibition (% of isolates)		
	No. zone (No activity)	8 – 10mm	11 – 14mm
10mg/ml	26 (72.2)	10 (27.8)	-
15mg/ml	22 (61.1)	12 (33.3)	2 (5.6)
20mg/ml	9 (25.0)	14 (38.9)	13 (36.1)
25mg/ml	9 (25.0)	11 (30.6)	16 (44.4)

Table 10. Antibacterial activity of crude extract of stem bark of *P. biglobosa* against MRSA isolates from bed

Concentration of extract	Diameter zone of inhibition (% of isolates)		
	No. zone (No activity)	8 – 10mm	11 – 14mm
10mg/ml	28 (58.3)	20 (41.7)	-
15mg/ml	21 (43.8)	20 (21.7)	7 (14.6)
20mg/ml	14(29.2)	13 (27.1)	21 (43.8)
25mg/ml	11 (22.9)	9 (18.8)	28 (58.3)

Comparing the plant parts: leaf, root and stem bark, it was observed in this study that the stem bark showed the greatest activity against the MRSA isolates tested. In accordance with the findings of this study, *Parkia biglobosa* has been reported to be rich in flavonoids, tannins and saponins [22], which are secondary metabolites known to have antibacterial activities. Millogo- Kone et al. [24] reported that the stem bark is rich in sterols, triterpenes, tannins, saponosides, anthocyanins, flavonoids, coumarins and reducing compounds while the leaf is rich in tannins, coumarins, anthocyanins, flavones and reducing compounds. Also, the crude extract of *Parkia biglobosa* root bark contains saponins, glycosides, tannins and a trace of alkaloids [25]. Since the presence of these metabolites in plants have been linked to the antimicrobial activities of the plants [26,27] it can therefore be inferred that these secondary metabolites may be responsible for the observed antibacterial activities. Further work with this plant could yield single chemical entities (SCES) with better antibacterial activities and greater potential as anti-staphylococcal agent.

4. CONCLUSION

There was high prevalence of MDR *S.aureus* isolates from the clinical and surveillance samples from the orthopaedic patients. In the search for alternative anti-staphylococcal agents from natural sources, *Parkia biglobosa* will be a possible candidate for further investigation.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Foster T. *Staphylococcus*. In: Barron's Medical Microbiology. Barron, S. et al., editors, 4th ed. Univ. of Texas Medical Branch; 1996.

2. Sabiti EN, Cobbina J. *Parkia biglobosa*: a potential multipurpose fodder tree legume in West Africa. The International Tree Crops Journal. 1992;7:113-139.
3. Agroforestry Database. International Centre for Research in Agroforestry (ICRAF); 2008.
4. Irvine FR. Wood Plants of Ghana. London: Oxford University Press. 1961;104.
5. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: 16th informational supplement. 2006;M100- S16. Wayne, PA.
6. Cheesbrough M. District Laboratory Practice in Tropical Countries, Part 2. Cambridge University Press. 2002;135-142.
7. Trease GE, Evans WC. Pharmacognosy. 15th ed. Brailliar Tridel can, Macmillan Publishers; 1989.
8. Harborne JB. Phytochemical Methods. 2nd ed. London: Chapman & Hull; 1991.
9. Price CS, Williams A, Philips G, Dayton M, Smith W, Morgan S. *Staphylococcus aureus* nasal colonization in pre operative orthopaedic out patients. Clin. Orthop. Relat Res. 2008;466:2824-2847.
10. Center for Disease Control and Prevention (1996). National Nosocomial Infection Surveillance system report data summary from October 1986 – April 1996 Atlanta (GA) US Department of Health and Human services; 1996.
11. Witte W, Braulke C, Heuck D, Cuny C. Analysis of nosocomial outbreaks with multiply and Methicillin resistant *Staphylococcus aureus* (MRSA) in Germany: implications for hospital hygiene. Infection. 1994;22(2):128-134.
12. Roberts JR, Catherine AH, Anna Poon Kimberly D, Jeremy A, Greene, Achi M. The economic impact of *Staph aureus* infection in New York city hospitals. Emerging Infectious Diseases. 1999;5(1).
13. Narezkina A, Edelstein I, Dekhnich A, Stratchounski L, Pimkin M, Palagin I. Prevalence of methicillin – resistant *Staphylococcus aureus* in different regions of Russia: results of multicenter study. 12th European Congress of Microbiology and Infectious Diseases; 2006.
14. Arif MA, Shahid AA, Shazia A, Irfan M. Nosocomial infections due to methicillin – resistant *Staphylococcus aureus* in hospital patients. Pak J Med Sci. 2007;23 (4):593 – 596.
15. Fridkin SK. Vancomycin intermediate and resistant *Staphylococcus aureus*: What the infectious disease specialists need to know. Clin. Infect. Dis. 2001;36:429-439.
16. Anupurba S, Sen R, Nath G, Sharma BM. Prevalence of Methicillin resistant *Staphylococcus aureus* in a tertiary referral hospital in Eastern Uttar Pradesh. Indian J. Med. Microbiol. 2003;21:49-51.
17. Umolu PI, Okoli EN, Izomoh IM. Antibiogram and β lactamase production of *Staphylococcus aureus* isolates from different human clinical specimens in Edo state, Nigeria. West Afr. Med. 2002;21(2):124-127.
18. Carmeli Y, Ehopoulus GM, Samore MH. Antecedent treatment with different antibiotic agents as a risk factor for vancomycin resistant Enterococcus. Emerg. Infect Dis. 2002;8:802-807.
19. Whitener CJ, Park SY, Brown FA. Vancomycin resistant *Staphylococcus aureus* in the absence of vancomycin exposure. Clin. Infec. Dis. 2004;38:1049-1055.
20. John CA, David LH. Outline of fractures. 10th ed. Churchill Livingstone. 1991;3-51.
21. Oyi AR. A study of antimicrobial and phytochemical properties of the latex of *Jathropa curcas* Linn (Euphorbiaceae) PhD Dissertation A.B.U. Zaria, Nigeria; 2001.
22. Ajaiyeoba EO. Phytochemical and Antibacterial Properties of *Parkia biglobosa* and *Parkia bicolor* leaf extracts. Afr. J. Biomed. Res. 2002;5:125-129.

23. Hall JB, Tomlinson HF, Oni PI, Buchy M, Aebischer DP. *Parkia biglobosa* a Monograph – School of Agriculture and Forest Sciences, University of Wales, Bangor, U.K.; 1997.
24. Millogo-Kone H, Guissou IP, Nacoulma O, Traone AS. Study of the antibacterial activity of *Parkia biglobosa* (Jacq) Benth. on *Staphylococcus aureus* Afr. J. of Trad. Comp. and Alt. Med. 2006;3(2):74-78.
25. El-Mahmood AM, Ameh JM. In vitro antibacterial activity of *Parkia biglobosa* (Jacq) Benth root bark extract against some microorganism associated with urinary tract infections. Afr. J. Biotechnol. 2007;6(11):1272-1275.
26. Lewis K, Ausubel FM. Prospects for plant derived antibacterials. Nat. Biotechnol. 2006;24(12):1504-1507.
27. Cowan MM. Plant products as antimicrobial agents. Clin. Microbial. Rev. 1999;12(4):564 – 582.

© 2013 Obajuluwa et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

The peer review history for this paper can be accessed here:
<http://www.sciencedomain.org/review-history.php?iid=234&id=14&aid=1411>